Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

Nucleic Acids Research

Volumn 46, Issue 4, 2018, Pages 1584-1600

  Shen, Xiulong ^a   Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; DOUBLE STRANDED DNA; DRISAPERSEN; ETEPLIRSEN; FITUSIRAN; FOMIVIRSEN; GALACTOSAMINE; GIVOSIRAN; GRN 163 L; IMETELSTAT; INCLISIRAN; INOTERSEN; IONIS HTTRX; LOCKED NUCLEIC ACID; LOMITAPIDE; MIPOMERSEN; MIRAVIRSEN; NANOPARTICLE; NUCLEOSIDE; NUSINERSEN; OBLIMERSEN; PATISIRAN; PEGAPTANIB; PHOSPHOROTHIOIC ACID; REVUSIRAN; RG 012; RIBOSE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLANESORSEN; DOUBLE STRANDED RNA; MICRORNA; PROTEIN;

ARTICLE; BINDING AFFINITY; CELL TRANSPORT; CHEMICAL MODIFICATION; DNA BINDING; DRUG ACCUMULATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG MECHANISM; DRUG TARGETING; DRUG TISSUE LEVEL; GENETIC COMPLEMENTATION; HUMAN; MOLECULAR RECOGNITION; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NUCLEIC ACID SYNTHESIS; PRIORITY JOURNAL; RNA INTERFERENCE; RNA RECOGNITION MOTIF; RNA SPLICING; SYSTEMIC THERAPY; TRANSLATION REGULATION; ALTERNATIVE RNA SPLICING; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); PROTEIN SYNTHESIS;

ALTERNATIVE SPLICING; CLINICAL TRIALS AS TOPIC; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS; PROTEINS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED;

EID: 85041308609     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkx1239     Document Type: Article

References (142)

1. Zamecnik, P. C., Stephenson, M. L. (1978) Inhibition of RousSarcoma virus replication and cell transformation by a specificoligonucleotide. Proc. Natl. Acad. Sci. U. S. A., 75, 280-284.
2. Crooke, S. T. (2017) Molecular mechanisms of antisenseoligonucleotides. Nucleic Acid Ther., 27, 70-77.
3. Juliano, R. L. (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res., 44, 6518-6548.
4. Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., Liang, X. H. (2017)Cellular uptake and trafficking of antisense oligonucleotides. Nat. Biotechnol., 35, 230-237.
5. Deleavey, G. F., Damha, M. J. (2012) Designing chemicallymodified oligonucleotides for targeted gene silencing. Chem. Biol., 19, 937-954.
6. Sharma, V. K., Watts, J. K. (2015) Oligonucleotide therapeutics:chemistry, delivery and clinical progress. Future Med. Chem., 7, 22221-2242.
7. Abramova, T. (2013) Frontiers and approaches to chemical synthesisof oligodeoxyribonucleotides. Molecules, 18, 1063-1075.
8. Eckstein, F. (2014) Phosphorothioates, essential components oftherapeutic oligonucleotides. Nucleic Acid Ther., 24, 374-387.
9. Dowdy, S. F. (2017) Overcoming cellular barriers for RNAtherapeutics. Nat. Biotechnol., 35, 222-229.
10. Iwamoto, N., Butler, D. C., Svrzikapa, N., Mohapatra, S., Zlatev, I., Sah, D. W., Standley, S. M., Lu, G., Apponi, L. H., Frank-Kamenetsky, M. et al. (2017) Control of phosphorothioatestereochemistry substantially increases the efficacy of antisenseoligonucleotides. Nat. Biotechnol., 35, 845-851.
11. Manoharan, M. (1999) 2-carbohydrate modifications in antisenseoligonucleotide therapy: Importance of conformation, configurationand conjugation. Biochim. Biophys. Acta, 1489, 117-130.
12. Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., Wengel, J. (1998) LNA (LockedNucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, 38ligomerization, unprecedented nucleic acid recognition. Tetrahedron, 54, 3607-3630.
13. Obika, S., Nanbu, D., Hari, Y., Oh, J. I., Morio, K. I., Doi, T., Imanishi, T. (1998) Stability and structural features of the duplexescontaining nucleoside analogues with a fixed N-type conformation, 2-O, 4-C-methyleneribonucleosides. Tetrahedron Lett., 39, 5401-5404.
14. Braasch, D. A., Corey, D. R. (2001) Locked nucleic acid (LNA):Fine-tuning the recognition of DNA and RNA. Chem. Biol., 8, 1-7.
15. Seth, P. P., Vasquez, G., Allerson, C. A., Berdeja, A., Gaus, H., Kinberger, G. A., Prakash, T. P., Migawa, M. T., Bhat, B., Swayze, E. E. (2010) Synthesis and biophysical evaluation of24-constrained 2O-methoxyethyl and 24;-constrained 2O-ethylnucleic acid analogues. J. Org. Chem., 75, 1569-1581.
16. Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M. et al. (2015)AZD9150, a next-generation antisense oligonucleotide inhibitor ofSTAT3 with early evidence of clinical activity in lymphoma and lungcancer. Sci. Transl. Med., 7, 314ra185.
17. Staarup, E. M., Fisker, P. N., Hedtjarn, M., Lindholm, M. W., Rosenbohm, C., Aarup, V., Hansen, H. F., Orum, H., Hansen, J. B., Koch, T. (2010) Short locked nucleic acid antisense oligonucleotidespotently reduce apoliprotein B mRNA and serum cholesterol inmice and non-human primates. Nucleic Acids Res., 38, 7100-7111.
18. Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., Høg, A., Worm, J., Hedtjarn, M., Souleimanian, N., Miller, P. et al. (2009)Efficient gene silencing by delivery of locked nucleic acid antisenseoligonucleotides, unassisted by transfection reagents. Nucleic AcidsRes., 38, e3.
19. Chen, Z., Monia, B. P., Corey, D. R. (2002) Telomerase inhibition, telomere shortening, decreased cell proliferation by cellpermeable 2 '-O-methoxyethyl oligonucleotides. J. Med. Chem., 45, 5423-5425.
20. Sehgal, A., Vainshaw, A., Fitzgerald, K. (2013) Liver as atherapeutic target for oligonucleotide therapeutics. J. Hepatol., 59, 1354-1359.
21. Srinivasan, S. K., Tewary, H. K., Iversen, P. L. (1995)Characterization of binding sites, extent of binding, druginteractions of oligonucleotides with albumin. Antisense Res. Dev., 5, 131-139.
22. Henry, S. P., Johnson, M., Zanardi, T. A., Fey, R., Auyeung, D., Lappin, P. B., Levin, A. A. (2012) Renal uptake and tolerability ofa 2-O-methoxyethyl modified antisense oligonucleotide (ISIS113715) in monkey. Toxicology, 301, 13-20.
23. Donner, A. J., Yeh, S. T., Hung, G., Graham, M. J., Crooke, R. M., Mullick, A. E. (2015) CD40 generation 2. antisense oligonucleotidetreatment attenuates doxorubicin-induced nephropathy and kidneyinflammation. Mol. Ther. Nucleic Acids, 4, e265.
24. Lima, W. F., Prakash, T. P., Murray, H. M., Kinberger, G. A., Li, W., Chappell, A. E., Li, C. S., Murray, S. F., Gaus, H., Seth, P. P. et al. (2012)Single-stranded siRNAs activate RNAi in animals. Cell, 150, 883-894.
25. Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H. B., Cleveland, D. W., Swayze, E. E., Lima, W. F., Crooke, S. T., Prakash, T. P., Corey, D. R. (2012) Single-stranded RNAs use RNAi to potently andallele-selectively inhibit mutant huntingtin expression. Cell, 150, 895-908.
26. Ly, S., Navaroli, D. M., Didiot, M. C., Cardia, J., Pandarinathan, L., Alterman, J. F., Fogarty, K., Standley, C., Lifshitz, L. M., Bellve, K. D. et al. (2017) Visualization of self-delivering hydrophobicallymodified siRNA cellular internalization. Nucleic Acids Res., 45, 15-25.
27. Sheridan, C. (2017) With Alnylam's amyloidosis success, RNAiapproval hopes soar. Nat. Biotechnol., 35, 995-997.
28. Nair, J. K., Willoughby, J. L., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Eil'in, A. V., Milstein, S. et al. (2014) Multivalent N-aceylgalactosamine-conjugated siRNAlocalizes in hepatocytes and elicits robust RNAi-mediated genesilencing. J. Am. Chem. Soc., 136, 16958-16961.
29. Tanowitz, M., Hettrick, L., Revenko, A., Kinberger, G. A., Prakash, T. P., Seth, P. P. (2017) Asialoglycoproteinreceptor 1mediates productive uptake of N-acetylgalactosamine-conjugatedand unconjugated phosphorothioate antisense oligonucleotides intoliver hepatocytes. Nucleic Acids Res., 45, 12388-12400.
30. Huang, Y. (2017) Preclinical and clinical advances ofGalNAc-decorated nucleic acid therapeutics. Mol. Ther. NucleicAcids, 6, 116-132.
31. Prakash, T. P., Graham, M. J., Yu, J., Carty, R., Low, A., Chappell, A., Schmidt, K., Zhao, C., Aghajan, M., Murray, H. F. et al. (2014)Targeted delivery of antisense oligonucleotides to hepatocytes usingtriantennary N-acetyl galactosamine improves potency 10-fold inmice. Nucleic Acids Res., 42, 8796-8807.
32. Schmidt, K., Prakash, T. P., Donner, A. J., Kinberger, G. A., Low, A., Ostergaard, M. E., Bell, M., Swayze, E. E., Seth, P. P. (2017)Characterizing the effect of GalNAc and phosphorothioatebackbone on binding of antisense oligonucleotides to theasialoglycoprotein receptor. Nucleic Acids Res., 45, 2294-2206.
33. Viney, N. J., Van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Rosie, Z. Y., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M. et al. (2016) Antisense oligonucleotides targetingapolipoprotein (a) in people with raised lipoprotein (a): Tworandomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, 388, 2239-2253.
34. Dsouza, A. A., Devarajan, P. V. (2015) Asialoglycoproteinreceptor mediated hepatocyte targeting-strategies and applications. J. Control. Release, 203, 126-139.
35. Dominski, Z., Kole, R. (1993) Restoration of correct splicing inthalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. U. S. A., 90, 8673-8677.
36. Havens, M. A., Hastings, M. L. (2016) Splice-switching antisenseoligonucleotides as therapeutic drugs. Nucleic Acids Res., 44, 6549-6563.
37. Wang, Z., Jeon, H. Y., Rigo, F., Bennett, C. F., Krainer, A. R. (2012)Manipulation of PK-M mutally exclusive alterative splicing byantisense oligonucleotides. Open Biol., 2, 120-133.
38. Vickers, T. A., Crooke, S. T. (2015) The rates of the major steps inthe molecular mechanism of RNase H1-dependent antisenseoligonucleotide induced degradation of RNA. Nucleic Acids Res., 43, 8955-8963.
39. Lennox, K. A., Behlke, M. A. (2016) Cellular localization of longnon-coding RNAs affects silencing by RNAi more than by antisenseoligonucleotides. Nucleic Acids Res., 44, 863-877.
40. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., Freier, S. M. (1993)Evaluation of 2-modified oligonucleotides containing 2-deoxy gapsas antisense inhibitors of gene expression. J. Biol. Chem., 268, 14514-14522.
41. Minshull, J., Hunt, T. (1986) The use of single-stranded DNA andRNase H to promote quantitative 'hybrid arrest of translation' ofmRNA/DNA Hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res., 14, 6433-6451.
42. Nakamura, H., Oda, Y., Iwai, S., Inoue, H., Ohtsuka, E., Kanaya, S., Kimura, S., Katsuda, C., Katayanagi, K., Morikawa, K. (1991)How does RNase H recognize a DNA. RNA hybrid? Proc. Natl. Acad. Sci. U. S. A., 88, 11535-11539.
43. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A. (2001)Duplexes of 21-nucleotide RNAs mediate RNA interference incultured mammalian cells. Nature, 411, 494-498.
44. Pratt, A. J., MacRae, I. J. (2009) The RNA-induced silencingcomplex: A versatile gene-silencing machine. J. Biol. Chem., 284, 17897-17901.
45. Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., Hammond, S. M., Joshua-Tor, L., Hannon, G. J. (2004)Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305, 1437-1441.
46. Meister, G. (2013) Argonaute proteins: Functional insights andemerging roles. Nat. Rev. Genet., 14, 447-459.
47. Wang, Y., Juranek, S., Li, H., Sheng, G., Tuschl, T., Patel, D. J. (2008) Structure of an argonaute silencing complex with aseed-containing guide DNA and target RNA duplex. Nature, 456, 921-926.
48. Khvorova, A., Watts, J. K. (2017) The chemical evolution ofoligonucleotide therapies of clinical utility. Nat. Biotechnol., 35, 238-248.
49. Corey, D. R. (2007) RNA learns from antisense. Nat. Chem. Biol., 3, 8-11.
50. Liu, J., Hu, J., Corey, D. R. (2012) Expanding the action of duplexRNAs into the nucleus: Redirecting alternative splicing. NucleicAcids Res., 40, 1240-1250.
51. Adams, R., Nicke, B., Pohlenz, H. D., Sohler, F. (2015)Deciphering seed sequence based off-target effects in a large-scaleRNAi reporter screen for E-cadherin expression. PLoS One, 10, e0137640.
52. Li, Z., Rana, T. M. (2014) Therapeutic targeting of miRNAs:current status and future challenges. Nat. Rev. Drug Discov., 13, 622-638.
53. Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S. et al. (2015) Anti-microRNA-21 oligonucleotides prevent Alportnephropathy progression by stimulating metabolic pathways. J. Clin. Invest., 125, 141-156.
54. Janssen, H. L., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y. et al. (2013) Treatment of HCV infection bytargeting microRNA. N. Engl. J. Med., 368, 1685-1694.
55. Gebert, L. F., Rebhan, M. A., Crivelli, S. E., Denzler, R., Stoffel, M., Hall, J. (2014) Miravirsen (SPC3649) can inhibit the biogenesis ofmiR-122. Nucleic Acids Res., 42, 609-621.
56. Ottosen, S., Parsley, T. B., Yang, L., Zeh, K., van Doorn, L. J., van derVeer, E., Raney, A. K., Hodges, M. R., Patick, A. K. (2015) In vitroantiviral activity and preclinical and clinical resistance profile ofmiravirsen, a novel anti-hepatitis C virus therapeutic targeting thehuman factor miR-122. Antimicrob. Agents Chemother., 59, 599-608.
57. Ree, M. H., Meer, A. J., Nuenen, A. C., Bruijne, J., Ottosen, S., Janssen, H. L., Kootstra, N. A., Reesink, H. W. (2016) Miravirsendosing in chronic hepatitis C patients results in decreasedmicroRNA-122 levels without affecting other microRNAs inplasma. Aliment. Pharmacol. Ther., 43, 102-113.
58. Zhou, J., Rossi, J. (2017) Aptamers as targeted therapeutics:current potential and challenges. Nat. Biotechnol., 16, 181-202.
59. Stein, C. A., Krieg, A. M. (1994) Problems in interpretation ofdata derived from in vitro and in vivo use of antisenseoligonucleotides. Antisense Res. Dev., 4, 67-69.
60. Crooke, S. T. (1996) Proof of mechanism of antisense drugs. Antisense Nucleic Acid Drug Dev., 6, 145-147.
61. Stein, C. A. (1999) Keeping the biotechnology of antisense in context. Nat. Biotechnol., 17, 209.
62. Crooke, S. T. (2000) Evaluating the mechanism of action ofantiproliferative antisense drugs. Antisense Nucleic Acid Drug Dev., 10, 123-126.
63. Myers, K. J., Dean, N. M. (2000) Sensible use of antisense: How touse oligonucleotides as research tools. Trends Pharm. Sci., 21, 19-23.
64. Stein, C. A. (2001) The experimental use of antisenseoligonucleotides: A guide for the perplexed. J. Clin. Invest., 108, 641-644.
65. Editorial (2003) Wither RNAi? Nat. Cell Biol., 5, 489-490.
66. Winkler, J., Stessl, M., Amartey, J., Noe, C. R. (2010) Off-targeteffects related to the phosphorothioate modification of nucleic acids. Chemmedchem, 5, 1344-1352.
67. de Fougerolles, A., Vornlocher, H. P., Maraganore, J., Lieberman, J. (2007) Interfering with disease: A progress report onsiRNA-based therapeutics. Nat. Rev. Drug Discov., 6, 443-453.
68. Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., Kay, M. A. (2006) Fatality inmice due to oversaturation of cellular microRNA/short hairpinRNA pathways. Nature, 441, 537-541.
69. Burel, S. A., Hart, C. E., Cauntay, P., Hsiao, J., Machemer, T., Katz, M., Watt, A., Bui, H. H., Younis, H., Sabripour, M. et al. (2016)Hepatotoxicity of high affinity gapmer antisense oligonucleotides ismediated by RNase H1 dependent promiscuous reduction of verylong pre-mRNA transcripts. Nucleic Acid Res., 44, 2093-2109.
70. Frazier, K. S. (2015) Antisense oligonucleotide therapies: Thepromise and the challenges from a toxicologic pathologistsperspective. Toxicol. Pathol., 43, 78-89.
71. Chi, X., Gatti, P., Papoian, T. (2017) Safety of antisenseoligonucleotide and siRNA-based therapeutics. Drug Discov. Today, 22, 823-833.
72. Crooke, S. T., Baker, B. F., Witzum, J. L., Kwoh, J., Pham, N. C., Salgado, N., McEvoy, B. W., Cheng, W., Hughes, S. G., Bhanot, S. et al. (2017) The effects of 2-O-methoxyethyl containing antisenseoligonucleotides on platelets in clinical trials. Nucleic Acid Ther., 27, 121-129.
73. Geary, R. S., Henry, S. P., Grillone, L. R. (2002) Fomivirsen:clinical Pharmacology and potential drug interactions. Clin. Pharmacokinet., 41, 255-260.
74. Jabs, D. A., Griffiths, P. D. (2002). Fomivirsen for the treatment ofcytomegalovirus retinitis. Am. J. Opthamol., 133, 552-556.
75. Cursiefen, C., Viaud, E., Bock, F., Geudelin, B., Ferry, A., Kadlecova, P., Levy, M., Al Mahmood, S., Colin, S., Thorin, E. et al. (2014) Aganirsen antisense oligonucleotide eye drops inhibitKaeratitis-induced corneal neovascularization and reduced need fortranplanation. The I-CAN study. Ophthamology, 121, 1683-1692.
76. Kim, R., Emi, M., Tababe, K., Toge, T. (2004) Therapeuticpotential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer, 101, 2491-2501.
77. Matsui, M., Corey, D. R. (2017) Non-coding RNAs as drugtargets. Nat. Rev. Drug Discov., 27, 87-94.
78. Benimetskaya, L., Lai, J. C., Khvorova, A., Wu, S., Hua, E., Miller, P., Zhang, L. M., Stein, C. A. (2004) Relative Bcl-2 independence ofdrug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin. Cancer Res., 10, 8371-8379.
79. Erson, E. M., Miller, P., Ilsley, D., Marshall, W., Khvorova, A., Stein, C. A., Benimetskaya, L. (2006) Gene profiling study ofG3139-and Bcl-2 targeting siRNAs identifies a unique G3139molecular signature. Cancer Gene Ther., 13, 406-414.
80. Westphal, S. P. (2003) Behind the mask. New Scientist, 179, 32-35.
81. Corey, D. R. (2009) Telomeres and telomerase: From discovery toclinical trials. Chem. Biol., 16, 1219-1223.
82. Ouellette, M. M., Wright, W. E., Shay, J. W. (2011) Targetingtelomerase-expressing cancer cells. J. Cell. Mol. Med., 15, 1433-1442.
83. Herbert, B., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., Corey, D. R. (1999) Inhibition of human telomerase inimmortal human cells leads to progressive telomere shortening andcell death. Proc. Natl. Acad. Sci. U. S. A., 96, 14276-14281.
84. Baerlocher, G. M., Leibundgut, E. O., Ottmann, O. G., Spitzer, G., Odenike, O., McDevitt, M. A., Roth, A., Daskalakiz, M., Burington, B., Stuart, M. et al. (2015) Telmoerase inhibitor imetelstatin patients with essential thrombocythemia. N. Eng. J. Med., 373, 920-928.
85. Tefferi, A., Lasho, T. L., Begna, K. H., Patnaik, M. M., Zblewski, D. L., Finke, C. M., Laborde, R. R., Wassie, E., Schimek, L., Hanson, C. A. et al. (2015) A pilot study of the telomerase inhibitor imetelstat formyelofibrosis. N. Eng. J. Med., 373, 908-919.
86. Tefferi, A., Al-Kali, A., Begna, K. H., Patnaik, M. M., Lasho, T. L., Rizo, A., Wan, Y., Hansen, C. A. (2016) Imetelstat therapy inrefractory anemia with ring sideroblasts with or withoutthrombocytosis. Blood Cancer J., 6, e405.
87. Duell, P. B., Santos, R. D., Kirwan, B-A., Witzum, J. L., Tsimikas, S. and Kastelein, J. J. P. (2016) Long term mipomersen treatment isassociated with a reduction in cardiovascular events in patients withfamilial hypercholesterolemia. J. Clin. Lipidol., 10, 1011-1021.
88. Rader, D. J., Kastelein, J. J. (2014) Lomitapide and mipomersen:two first-in-class drugs for reducing low-density lipoproteincholesterol in patients with homozygous familialhypercholesterolemia. Circulation, 129, 1022-1032.
89. Won, J. I., Zhang, J., Tecson, K. M., McCullough, P. A. (2017)Balancing low-density lipoprotein cholesterol reduction andhepatotoxicity with lomitapide mesylate and mipomersen in patientswith homozygous familial hypercholesterolemia. Rev. Cardiovasc. Med., 18, 21-28.
90. Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Ko, S. and Perera, R. J. (2005) An apolipoprotein B antisenseoligonucleotide lowers LDL cholesterol in hyperlipidemic micewithout causing hepatic steatosis. J. Lipid Res., 46, 872-884.
91. Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., Crooke, R. M. (2006) Potentreduction of apolipoprotein B and low-density cholesterol byshort-term administration of an antisense inhibitor ofapolipoprotein B. Circulation, 114, 1729-1735.
92. Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., Wilton, S. D. (2001)Antisense-induced exon skipping and synthesis of dystrophin in themdx mouse. Proc. Natl. Acad. Sci. U. S. A., 98, 42-47.
93. Kole, R., Krieg, A. M. (2015) Exon skipping therapy forDuchenne muscular dystrophy. Adv. Drug. Deliv. Rev., 87, 104-107.
94. Goemans, N., Tulinius, M., Kroksmark, A-K., Wilson, R., van denHauwe, M., Campion, G. (2017) Comparison of ambulatorycapacity and disease progression of Duchenne muscular dystrophysubjects enrolled in the drisapersen DMD114673 study with amatched natural history cohart of subjects on daily corticosteroids. Neuromuscul. Disord., 27, 203-213.
95. Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, L. P., Kaye, E. M., Mercuri, E., (2016) Longitudinal effect ofeteplirsen versus historical control on ambulation in Duchennemuscular dystrophy. Ann. Neurol., 79, 257-271.
96. Stein, C. A., Castanotto, D. (2017) FDA-approvedoligonucleotide therapies in 2017. Mol. Ther., 25, 1069-1075.
97. Kesselheim, A. S., Avorn, J. (2016) Appoving a problematicmuscular dystrophy drug Implications for FDA policy. J. Am. Med. Assoc., 316, 2357-2358.
98. Aartsma-Rus, A., Krieg, A. M. (2017) FDA approves eteplirsenfor Duchenne muscular dystrophy: The next chapter in the eteplirsensaga. Nucleic Acid Ther., 27, 1-3.
99. Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E. (2016) Longitudinal effect ofeteplirsen versus historical control on ambulation in Duchennemuscular dystrophy. Ann. Neurol., 79, 257-271.
100. Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., VanDeutekom, J., van Ommen, G. J., Den Dunnen, J. T. (2009)Theoretic applicability of antisense-mediated exon skipping forDuchenne muscular dystrophy mutations. Hum. Mutat., 30, 293-299.
101. Mendell, J. R., Rodino-Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J. et al. (2013)Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol., 74, 637-647.
102. Unger, E. F., Califf, R. M. (2017) Regarding "Eteplirsen for thetreatment of Duchenne muscular dystrophy". Ann. Neurol., 81, 162-164.
103. Irwin, A. N., Herink, M. C. (2017) Eteplirsen for the treatment ofDuchenne muscular dystrophy: Quality of evidence concerns-analternative viewpoint. Pharmacotherapy, 37, e109-e111.
104. Betts, C., Saleh, A. F., Arzumanov, A. A., Hammond, S. M., Godfrey, C., Coursindel, T., Gait, M. J., Wood, M. J. (2012)Pip6-PMO, a new generation of peptide-oligonucleotide conjugateswith improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids, 1, e38.
105. Lehto, T., Castillo Alvarez, A., Gauck, S., Gait, M. J., Coursindel, T., Wood, M. J., Lebleu, B., Boisguerin, P. (2013) Cellular traffickingdetermines the exon skipping activity of Pip6a-PMO in mdx skeletaland cardiac muscle cells. Nucleic Acids Res., 42, 3207-3217.
106. Faravelli, I., Nizzardo, M., Comi, G. P., Corti, S. (2015) Spinalmuscular atrophy-recent therapeutic advances for an old challenge. Nat. Rev. Neurosci., 11, 351-359.
107. Lim, S. R., Hertel, K. J. (2001) Modulation of survival motorneuron pre-mRNA splicing by inhibition of alternative 3-splice sitepairing. J. Biol. Chem., 48, 45476-45483.
108. Cartegni, L., Krainer, A. R. (2002) Disruption of anSF2/ASF-dependent exonic splicing enhancer in SMN2 causesspinal muscular atrophy in the absence of SMN1. Nat. Genet., 30, 377-384.
109. Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., Krainer, A. R. (2007) Enhancement of SMN2 exon 7 inclusion by antisenseoligonucleotides targeting the exon. PLoS Biol., 5, 729-744.
110. Hache, M., Swoboda, K. J., Sethna, N., Farrow-Gillespie, A., Khandji, A., Xia, S., Bishop, K. M. (2016) Intrathecal injections inchildren with spinal muscular atrophy: Nusinersen clinical trialexperience. J. Child. Neurol., 31, 899-906.
111. Corey, D. R. (2017) Nusinersen, an antisense oligonucleotide drugfor spinal muscular atrophy. Nat. Neurosci., 20, 497-499.
112. Aartsma-Rus, A. (2017) FDA approval of nusinersen for spinalmuscular atrophy makes 2016 the year of splice modulatingoligonucleotides. Nucleic Acid Ther., 27, 67-69.
113. Scoto, M., Finkel, R. S., Mercuri, E., Muntoni, F. (2017)Therapeutic approaches for spinal muscular atrophy (SMA). GeneTher., 24, 514-519.
114. Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E. et al. (2017) Nusinersen versus sham control in infantile-onset spinalmuscular atrophy. N. Engl. J. Med., 377, 1723-1732.
115. Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K. et al. (2017) Single-dose gene-replacement therapy forspinal muscular atrophy. N. Engl. J. Med., 377, 1713-1722.
116. van der Ploeg, A. T. (2017) The dilemma of two innovative therapiesfor spinal muscular atrophy. N. Engl. J. Med., 377, 1786-1787.
117. Niemietz, C., Chandhok, G., Schmidt, H. (2015) Therapeuticoligonucleotides targeting liver disease: TTR amyloidosis. Molecules, 20, 17944-17975.
118. Ackermann, E. J., Guo, S., Benson, M. D., Booten, S., Freier, S., Hughes, S. G., Kim, T. W., Kwoh, J. T., Matson, J., Norris, D. et al. (2016) Suppressing transthyretin production in mice, monkeys andhumans using 2nd-generation antisense oligonucleotides. Amyloid, 23, 148-157.
119. Zimmerman, T. S., Karsten, V., Chan, A., Chiesa, J., Boyce, M., Bettencourt, B. R., Huabarat, R., Nochur, S., Vaishnaw, A., Gollob, J. (2017) Clinical proof of concept for a novelhepatocyte-targeting GalNAc-siRNA conjugate. Mol. Ther., 25, 71-78.
120. Garber, K. (2016) Alnylam terminates revusiran program, stockplummets. Nat. Biotechnol., 34, 1213-1214.
121. Tam, Y. K., Madden, T. D., Hope, M. J. (2016) Pieter Cullis' questfor a lipid-based, fusogenic delivery system for nucleic acidtherapeutics: Success with siRNA so what about mRNA? J. DrugTarget, 24, 774-779.
122. Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R. et al. (2015) Efficacy and safety of patisiran forfamial amyloidotic polyneuropathy: A phase II multi-dose study. Orphanet J. Rare Dis., 10, 109.
123. Pasi, K. J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M. D., Lissitchkov, T., Bevan, D., Austin, S., Hay, C. R., Hegemann, I. et al. (2017) Targeting antithrombin in hemophilia A or B with RNAitherapy. N. Eng. J. Med., 377, 819-828.
124. Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P., Turner, T., Visseren, F. L. et al. (2017) Inclisiran in patients at high cardiovascular risk with elevatedLDL cholesterol. N. Eng. J. Med., 376, 1430-1440.
125. Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A. et al. (2017) A highly durable RNAi therapeutic inhibitorof PCSK9. N. Engl. J. Med., 376, 41-51.
126. Yasuda, M., Gan, L., Chen, B., Kadirvel, S., Yu, C., Phillips, J. D., New, M. I., Liebow, A., Fitzgerald, K., Querbes, W. et al. (2014)RNAi-mediated silencing of hepatic Alas1 effectively prevents andtreats the induced acute attacks in acute intermittent porphyriamice. Proc. Natl. Acad. Sci. U. S. A., 111, 7777-7782.
127. Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K. et al. (2015)Preclinical development of a subcutaneous ALAS1 RNAitherapeutic for treatment of hepatic porphyrias using circulatingRNA quantification. Mol. Ther. Nucleic Acids, 4, e263.
128. Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., Rubinsztein, D. C. (2017) Huntington's disease: Mechanisms ofpathogenesis and therapeutic strategies. Cold Spring Harb. Perspect. Med., 7, a024240.
129. De Souuza, E. B., Cload, S. T., Pendergrast, P. S., Sah, D. W. (2009)Novel therapeutic modalities to address nondruggable proteininteraction targets. Neuropsychopharmacology, 34, 142-158.
130. Pfister, E. L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., Difiglia, M., Landwhrmeyer, B., Vonsattel, J-P., Zamore, P. D., Aronin, N. (2009) Five siRNAs targeting three SNPs may providetherapy for three-quarters of Huntington's Disease patients. Curr. Biol., 19, 774-778.
131. Hu, J., Corey, D. R. (2010) Allele-selective inhibition of huntingtinexpression by switching to an miRNA-like RNAi mechanism. Chem. Biol., 17, 1183-1188.
132. Gagnon, K. T., Pendergraff, H. M., deleavey, G. F., Swayze, E. E., Potier, P., Randolph, J., Roesch, E. B., Chattopadhyaya, J., Damha, M. J., Bennett, C. F. et al. (2010) Allele-selective inhibition ofmutant huntingtin expression with antisense oligonucleotidestargeting the expanding CAG repeat. Biochemistry, 49, 10166-10178.
133. Skotte, N. H., Southwell, A. L., Ostergaard, M. E., Carroll, J. B., Warby, S. C., Doty, C. N., Petoukhov, E., Vaid, K., Kordasiewicz, H., Watt, A. T. et al. (2014) Allele-specific suppression of mutanthuntingtin using antisense oligonucleotides: Providing a therapeuticoption for all huntingtin disease patients. PLoS One, 9, e107434.
134. Miller, J. R. C., Pfister, E. L., Liu, W., Andre, R., Trager, U., Kennington, L. A., Lo, K., Dijkstra, S., Macdonald, D., Ostroff, G. et al. (2017) Allele-selective suppression of mutant huntingtin inprimary human blood cells. Sci. Rep., 7, 46740.
135. Wild, E. J., Tabrizi, S. J. (2017) Therapies targeting DNA andRNA in Huntington's disease. Lancet Neurol., 16, 837-847.
136. Boudreau, R. L., McBride, J. L., Martins, I., Shen, S., Xing, Y., Carter, B. J., Davidson, B. L. (2009) Nonallele-specific silencing ofmutant and wild-type hunting demonstrates therapeutic efficacy inHuntington's Disease mice. Mol. Ther., 17, 1053-1063.
137. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouileet, E., Luthi-Cater, R., Hantraye, P. et al. (2009)Sustained effects of nonallele-specific huntingtin silencing. Ann. Neurol., 65, 276-285.
138. Kordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. A., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S. et al. (2012) Sustained therapeutic reversal ofHuntington's Disease by transient repression of huntingtinsynthesis. Neuron, 74, 1031-1044.
139. Nikan, M., Osborn, M. F., Coles, A. H., Godinho, B. M., Hall, L. M., Haraszti, M. R., Echeverria, D., Aronin, N., Khvorova, A. (2016)Docosahexaenoic acid conjugation enhances distribution and safetyof siRNA upon local administration in mouse brain. Mol. Ther. Nucleic Acids, 5, e344.
140. Reiner, Z. (2017) Hypertriglyceridaemia and risk of coronary arterydisease. Nat. Rev. Cardiol., 14, 401-411.
141. Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W. et al. (2016) Antisense-mediated lowering of plasmaapolipoprotein C-III by volanesorsen improves dyslipidemia andinsulin sensitivity in type 2 diabetes. Diabetes Care, 39, 1408-1415.
142. Yang, X., Liee, S-R., Choi, Y-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witzum, J. L., Tsimikas, S. (2016) Reduction inlipoprotein-associated apoC-III levels following volanesorsentherapy: Phase 2 randomized trials results. J. Lipid Res., 57, 706-713.